🎉 M&A multiples are live!
Check it out!

Verrica Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Verrica Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Verrica Pharmaceuticals Overview

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.


Founded

2013

HQ

United States of America
Employees

71

Website

verrica.com

Financials

LTM Revenue $10.1M

LTM EBITDA n/a

EV

$50.4M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Verrica Pharmaceuticals Financials

Verrica Pharmaceuticals has a last 12-month revenue of $10.1M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Verrica Pharmaceuticals achieved revenue of $7.6M and an EBITDA of -$65.9M.

Verrica Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Verrica Pharmaceuticals valuation multiples based on analyst estimates

Verrica Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $5.1M $7.6M XXX XXX XXX
Gross Profit $8.3M $4.4M XXX XXX XXX
Gross Margin 162% 58% XXX XXX XXX
EBITDA -$62.2M -$65.9M XXX XXX XXX
EBITDA Margin -1214% -871% XXX XXX XXX
Net Profit -$24.5M -$67.0M XXX XXX XXX
Net Margin -478% -885% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Verrica Pharmaceuticals Stock Performance

As of April 15, 2025, Verrica Pharmaceuticals's stock price is $1.

Verrica Pharmaceuticals has current market cap of $50.7M, and EV of $50.4M.

See Verrica Pharmaceuticals trading valuation data

Verrica Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$50.4M $50.7M XXX XXX XXX XXX $-1.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Verrica Pharmaceuticals Valuation Multiples

As of April 15, 2025, Verrica Pharmaceuticals has market cap of $50.7M and EV of $50.4M.

Verrica Pharmaceuticals's trades at 5.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Verrica Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Verrica Pharmaceuticals and 10K+ public comps

Verrica Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $50.4M XXX XXX XXX
EV/Revenue 6.7x XXX XXX XXX
EV/EBITDA -0.8x XXX XXX XXX
P/E -0.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -0.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Verrica Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Verrica Pharmaceuticals Valuation Multiples

Verrica Pharmaceuticals's NTM/LTM revenue growth is 106%

Verrica Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.0M for the same period.

Over next 12 months, Verrica Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Verrica Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Verrica Pharmaceuticals and other 10K+ public comps

Verrica Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 48% XXX XXX XXX XXX
EBITDA Margin -871% XXX XXX XXX XXX
EBITDA Growth 6% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -765% XXX XXX XXX XXX
Revenue per Employee $0.1M XXX XXX XXX XXX
Opex per Employee $1.0M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 156% XXX XXX XXX XXX
Opex to Revenue 934% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Verrica Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Verrica Pharmaceuticals M&A and Investment Activity

Verrica Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Verrica Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Verrica Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Verrica Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Verrica Pharmaceuticals

When was Verrica Pharmaceuticals founded? Verrica Pharmaceuticals was founded in 2013.
Where is Verrica Pharmaceuticals headquartered? Verrica Pharmaceuticals is headquartered in United States of America.
How many employees does Verrica Pharmaceuticals have? As of today, Verrica Pharmaceuticals has 71 employees.
Who is the CEO of Verrica Pharmaceuticals? Verrica Pharmaceuticals's CEO is Dr. Jayson Rieger.
Is Verrica Pharmaceuticals publicy listed? Yes, Verrica Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Verrica Pharmaceuticals? Verrica Pharmaceuticals trades under VRCA ticker.
When did Verrica Pharmaceuticals go public? Verrica Pharmaceuticals went public in 2018.
Who are competitors of Verrica Pharmaceuticals? Similar companies to Verrica Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Verrica Pharmaceuticals? Verrica Pharmaceuticals's current market cap is $50.7M
What is the current revenue of Verrica Pharmaceuticals? Verrica Pharmaceuticals's last 12-month revenue is $10.1M.
What is the current EV/Revenue multiple of Verrica Pharmaceuticals? Current revenue multiple of Verrica Pharmaceuticals is 5.0x.
What is the current revenue growth of Verrica Pharmaceuticals? Verrica Pharmaceuticals revenue growth between 2023 and 2024 was 48%.
Is Verrica Pharmaceuticals profitable? Yes, Verrica Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.